Clinical Trials Logo

Kidney Neoplasms clinical trials

View clinical trials related to Kidney Neoplasms.

Filter by:

NCT ID: NCT00045487 Completed - Kidney Cancer Clinical Trials

Erlotinib in Treating Patients With Advanced Kidney Cancer

OSI-774
Start date: June 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have advanced kidney cancer.

NCT ID: NCT00045370 Completed - Kidney Cancer Clinical Trials

Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Start date: April 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as interferon alfa use different ways to stimulate the immune system and stop cancer cells from growing. Combining biological therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with biological therapy in treating patients who have locally advanced or metastatic kidney cancer.

NCT ID: NCT00045279 Completed - Kidney Cancer Clinical Trials

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Start date: April 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.

NCT ID: NCT00042965 Completed - Kidney Cancer Clinical Trials

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Start date: October 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining capecitabine with gemcitabine in treating patients who have metastatic kidney cancer.

NCT ID: NCT00041106 Completed - Clinical trials for Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Start date: May 2002
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the tumor. Combining chemotherapy with gefitinib may kill more tumor cells. Phase II trial to study the effectiveness of combining chemotherapy with gefitinib in treating patients who have metastatic transitional cell cancer of the urothelium

NCT ID: NCT00039429 Completed - Kidney Cancer Clinical Trials

Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

Start date: July 14, 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well atrasentan works in treating patients with locally recurrent or metastatic kidney cancer.

NCT ID: NCT00039169 Active, not recruiting - Kidney Cancer Clinical Trials

BAY 59-8862 in Treating Patients With Advanced Kidney Cancer

Start date: December 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer.

NCT ID: NCT00039052 Completed - Breast Cancer Clinical Trials

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in treating patients who have recurrent or metastatic kidney cancer, non-small cell lung cancer, or breast cancer that has not responded to previous treatment.

NCT ID: NCT00035243 Completed - Kidney Neoplasms Clinical Trials

EPO906 Therapy in Patients With Advanced Kidney Cancer

Start date: April 2002
Phase: Phase 2
Study type: Interventional

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.

NCT ID: NCT00034281 Completed - Breast Neoplasm Clinical Trials

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Start date: June 2002
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.